OmniAb Inc. has released a presentation highlighting the launch of its new OmniUltra platform. The presentation was delivered at the Antibody Engineering & Therapeutics Conference in San Diego and featured contributions from key company executives and scientists, including CEO Matt Foehr, CFO Kurt Gustafson, and SVP of Exploratory Research Yasmina Abdiche, PhD. The OmniUltra platform is described as a novel in vivo technology for the discovery of mini-proteins and structured peptides, with a focus on identifying ultralong CDRH3 antibodies and expanding epitope coverage. The presentation covered the scientific advancements and potential applications of the platform in antibody and peptide therapeutic discovery. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OmniAb Inc. published the original content used to generate this news brief on December 15, 2025, and is solely responsible for the information contained therein.
Comments